H3K9me3 drug
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (14)
Papers in which this entity is mentioned.
- Advancing regulatory variant effect prediction with AlphaGenome. (2026)
- LINE-1 retrotransposons mediate cis-acting transcriptional control in human pluripotent stem cells and regulate early brain development. (2025)
- Enhancer activation from transposable elements in extrachromosomal DNA. (2025)
- Nucleotide Transformer: building and evaluating robust foundation models for human genomics. (2025)
- Transcription start sites experience a high influx of heritable variants fueled by early development. (2025)
- Nanopore sequencing technology, bioinformatics and applications. (2021)
- Programmed suppression of oxidative phosphorylation and mitochondrial function by gestational alcohol exposure correlate with widespread increases in H3K9me2 that do not suppress transcription. (2021)
- Genetic compensation triggered by mutant mRNA degradation. (2019)
- Universal Patterns of Selection in Cancer and Somatic Tissues. (2017)
- Orthotopic patient-derived xenografts of paediatric solid tumours. (2017)
- ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. (2012)
- An integrated encyclopedia of DNA elements in the human genome. (2012)
- Transcriptional and epigenetic mechanisms of addiction. (2011)
- Model-based analysis of ChIP-Seq (MACS). (2008)
Merged raw entities (1)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| h3k9me3 | drug | 42 | 173 |